The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
EMPAVELI (Swedish Orphan Biovitrum Pty Ltd)
Product name
EMPAVELI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
83 (255 working days)
Active ingredients
pegcetacoplan
Registration type
EOI
Indication
EMPAVELI is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH).